Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Dermatology ; 232(3): 326-33, 2016.
Article in English | MEDLINE | ID: mdl-27093295

ABSTRACT

BACKGROUND: Low adherence to therapies in psoriasis decreases treatment outcomes and increases the total health care costs. In spite of the wide use of biologic agents, patients' adherence to these drugs has not been extensively investigated. OBJECTIVE: The aim of this study is to measure adherence to the biologic drugs in a population of patients treated for psoriasis vulgaris using the medication possession ratio (MPR) index and to survey patients' attitudes to the treatment. METHODS: This is a single-center study on 247 patients with psoriasis vulgaris treated with adalimumab (n = 113), etanercept (n = 39), and ustekinumab (n = 95). MPR calculation was calculated monthly based on the hospital records documenting the dispensing of biologics to the patients. Clinical data [Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), presence of psoriatic arthritis, concomitant treatment, and cause for treatment discontinuation] were obtained from the national database DERMBIO. Patients' attitudes and beliefs were measured using the Medication Adherence Rating Scale (MARS). RESULTS: A total of 93.5% of all patients had an MPR ≥0.8, indicating very good adherence. MPR was independent of patients' age, gender, median PASI or DLQI score, concomitant diagnosis of psoriatic arthritis, or treatment with methotrexate. MPR for etanercept was slightly lower than that for ustekinumab and adalimumab. The MARS questionnaire documented satisfactory understanding of the treatment and its adverse effects, and positive attitudes to the treatment. CONCLUSION: Adherence to biologic therapies is very high in patients with psoriasis, which is consistent with a positive attitude to the treatment.


Subject(s)
Adalimumab/therapeutic use , Biological Factors/therapeutic use , Biological Therapy/methods , Etanercept/therapeutic use , Patient Compliance , Psoriasis/drug therapy , Adult , Anti-Inflammatory Agents/therapeutic use , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Surveys and Questionnaires
2.
Opt Lett ; 32(15): 2082-4, 2007 Aug 01.
Article in English | MEDLINE | ID: mdl-17671543

ABSTRACT

We demonstrate high-efficiency, wideband-tunable, laser-ablated long-period fiber gratings that use an optical polymer overlay. Portions of the fiber cladding are periodically removed by CO(2) laser pulses to induce periodic index changes for coupling the core mode into cladding modes. An optical polymer with a high thermo-optic coefficient with a dispersion distinct from that of silica is used on a deep-ablated cladding structure so that the effective indices of cladding modes become dispersive and the resonant wavelengths can be efficiently tuned. The tuning efficiency can be as high as 15.8 nm/ degrees C, and the tuning range can be wider than 105 nm (1545-1650 nm).

3.
Appl Opt ; 44(9): 1529-32, 2005 Mar 20.
Article in English | MEDLINE | ID: mdl-15813252

ABSTRACT

A new design for a Fabry-Perot-based array filter for wavelength-division multiplexing (WDM) applications is proposed. The device is composed of two partially reflective mirrors; the surface of one of the mirrors is stepwise. Not only does the configuration of multiple air-gap cavities into a single unit provide wavelength tunability but the channel numbers can be expanded. A four-channel multiplexer has been demonstrated. The results revealed that a compact and cost-effective WDM device should be easily attainable.

SELECTION OF CITATIONS
SEARCH DETAIL
...